The effect of epibatidine on spontaneous and evoked neurotransmitter release in the mouse and guinea pig isolated vas deferens by Williams, DJ et al.
 
 
University of Birmingham
The effect of epibatidine on spontaneous and
evoked neurotransmitter release in the mouse and
guinea pig isolated vas deferens
Williams, DJ; Brain, Keith; Cunnane, TC
DOI:
10.1038/sj.bjp.0707183
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Williams, DJ, Brain, K & Cunnane, TC 2007, 'The effect of epibatidine on spontaneous and evoked
neurotransmitter release in the mouse and guinea pig isolated vas deferens', British Journal of Pharmacology,
vol. 150, no. 7, pp. 906-912. https://doi.org/10.1038/sj.bjp.0707183
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Wiley Gold article. This version is published in British Journal of Pharmacology
Volume 150, Issue 7, pages 906–912, (April 2007) DOI: http://dx.doi.org/10.1038/sj.bjp.0707183. This article is licensed under a CC-BY
licence. The funders were Wellcome Trust (TCC and KLB) and a MRC studentship (DJW).
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
RESEARCH PAPER
The effect of epibatidine on spontaneous and
evoked neurotransmitter release in the mouse and
guinea pig isolated vas deferens
DJ Williams, KL Brain and TC Cunnane
Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, UK
Background and purpose: Nicotinic agonists increase sympathetic field-stimulus-evoked contraction of the rodent vas
deferens, presumably by increasing evoked neurotransmitter release. This presumption was tested in two species.
Experimental approach: The effect of the nicotinic acetylcholine receptor (nAChR) agonist epibatidine on neurotransmitter
release in mouse and guinea pig isolated vas deferens was investigated using contraction studies and conventional intracellular
recording techniques.
Key results: In 12 of 14 mouse vasa deferentia, slow bath application of epibatidine (100 nM) had no significant effect
on excitatory junction potential (EJP) amplitude and spontaneous EJP (SEJP) frequency. However, rapid application of
epibatidine to the mouse vas deferens caused an increase in SEJP frequency (by 530%), with no effect on EJP amplitude.
Despite the absence of an effect on EJPs, electrically-evoked contractions of the mouse vas deferens were significantly increased
in the presence of epibatidine (by 50%). A transient contraction was reliably induced by a higher epibatidine concentration
(1 mM). This contraction was significantly reduced in the presence of prazosin, tetrodotoxin, or a,b-methyleneATP. Epibatidine
did not induce a contraction in the presence of a combination of prazosin, a,b-methyleneATP and cyclopentolate. In
guinea pig vasa deferentia, bath-applied epibatidine potentiated EJP amplitude in a biphasic pattern, lasting for at least
30minutes.
Conclusion and implications: The nAChR-mediated augmentation of neurogenic contraction is indeed prejunctional, but in
the mouse arises from an increase in spontaneous neurotransmitter release that primes smooth muscle for subsequent
contraction, while in the guinea pig there is a direct augmentation of evoked neurotransmitter (ATP) release.
British Journal of Pharmacology (2007) 150, 906–912. doi:10.1038/sj.bjp.0707183; published online 26 February 2007
Keywords: prejunctional; nicotinic; epibatidine; intracellular recording; mouse; guinea pig; vas deferens; sympathetic;
electrophysiology; neurotransmission
Abbreviations: a,b-MeATP, a, b-MethyleneATP; EJPs, excitatory junction potentials; nAChRs, nicotinic acetylcholine receptors;
NA, noradrenaline; PSS, physiological saline solution; RMP, resting membrane potential; SEJPs, spontaneous
excitatory junction potentials; TTX, tetrodotoxin
Introduction
The increase in neurotransmitter release that follows the
activation of nicotinic acetylcholine receptors (nAChRs) on
central (Pidoplichko et al., 1997) and peripheral (Rose et al.,
1999) nerve terminals contributes to nicotine dependence.
Furthermore, the activation of nAChRs located on sympa-
thetic nerves is thought to be partially responsible for the
detrimental effects of nicotine on cardiac function (Haass
and Kubler, 1997). Despite these powerful effects, the
mechanisms involved in the nicotinic potentiation of
neurotransmitter release remains to be fully elucidated.
The rodent vas deferens has a rich innervation of
sympathetic nerves (Sjo¨strand, 1965) and exposure of the
vas deferens to nAChR agonists has previously been shown
to evoke neurotransmitter release. This increase in neuro-
transmitter release leads to both a transient contraction and
a potentiation of electrically evoked contraction in guinea
pig (Todorov et al., 1991; von Ku¨gelgen and Starke, 1991b)
and a potentiation of electrically evoked contraction in
mouse (Brain et al., 2001). For these reasons, the rodent vas
deferens provides a good model to investigate the effect of
nAChR activation on sympathetic neurotransmitter release
in an intact tissue. In this study, epibatidine, a potent and
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specific nAChR nicotinic agonist with no other known
actions (Badio and Daly, 1994), was chosen to investigate
nAChR activation.
Methods
Tissue preparation
Vasa deferentia were removed from 8–12-week-old Balb/c
mice or 300–600 g guinea pigs which were killed by cervical
dislocation in accordance with the guidelines of the UK
Animal (Scientific Procedures) Act 1986. The prostatic
quarter of each vas deferens was removed to ensure that no
sympathetic ganglia were present in the preparation. The
bathing physiological saline solution (PSS) contained: NaCl
118.4mM, NaHCO3 25.0mM, NaH2PO4 1.13mM, CaCl2
1.8mM, KCl 4.7mM, MgCl2 1.3mM and glucose 11.1mM.
The solution was gassed with a mixture of 95% O2 and 5%
CO2 to pH 7.4 and maintained at a temperature of 35–371C.
Contraction studies
Each vas deferens was mounted in a 5ml organ bath (Letica
Scientific Instruments, Hospitalet, Spain) under a tension of
9.8mN and the isometric contraction of the longitudinal
smooth muscle layer was measured using a force transducer
(Letica Scientific Instruments, Spain). The preparations
were washed with fresh PSS every 20min and left to
equilibrate for 60min before the experiment. Field stimuli
were applied to the preparation through platinum ring
electrodes positioned at the prostatic end of the vas deferens.
Contractions were evoked by five stimuli at 10Hz (95V
amplitude and 0.5ms pulse width) and were delivered every
30 s using a custom-built digital stimulator (Department of
Pharmacology, Oxford, UK). To ensure that the contractions
were neurogenic, tetrodotoxin (TTX) sensitivity was tested.
Following incubation with TTX (300nM) for 40min, elec-
trically evoked contractions were abolished (number of
preparations (nv)¼6; see Figure 4aii). Drugs were added
directly to the organ bath as a bolus in a small volume
(o100 ml). Contractions were recorded using a PowerLab 4SP
data acquisition system (AD Instruments, Chalgrove,
Oxfordshire, UK) connected to a G3 computer (Apple)
running Chart 4 software (AD Instruments, UK).
Electrophysiological studies
Conventional intracellular recording techniques were used
to record excitatory junction potentials (EJPs) in smooth
muscle cells. The vas deferens was carefully pinned to the
Sylgard (Dow-Corning, Allesley, Coventry, UK) covered base
of a 5-ml Perspex organ chamber perfused with PSS at a rate
of 2ml/min. Drugs were added to the preparations either by
slow bath application or rapid application. For slow bath
application, drugs were added to the organ chamber by
exchanging the perfusing PSS to one containing the drugs at
the required final bath concentration. For rapid application,
a 2-ml solution of warmed and gassed PSS containing the
drug was added using a Gilson pipette directly to the organ
chamber. To ensure adequate mixing, the volume of the
superfusate was reduced to a minimum (1ml) and the
epibatidine solution was prepared and added to the organ
bath at the highest volume possible (2ml). To prevent
dilution of epibatidine, the superfusion system was stopped
while recording in the presence of epibatidine.
EJPs were evoked by electrical stimuli (pulse width 0.1ms,
15V amplitude and supramaximal for axon recruitment)
were delivered through a pair of platinum electrodes
positioned around the prostatic end of the vas deferens.
The stimuli were generated with a digital stimulator
(Applegarth Instruments, Oxford, UK) coupled to an
optically isolated stimulus unit.
The membrane potential of individual smooth muscle
cells was recorded using a sharp microelectrode. Micro-
electrodes were connected by an Ag/AgCl wire to the input
headstage of an Axoclamp 2B (Molecular Devices, Sunny-
vale, CA, USA). The data were digitised using a PowerLab 4SP
(AD Instruments, UK) and recorded on a G4 computer
(Apple) with Chart 5 software (AD Instruments, UK).
Microelectrodes were pulled from borosilicate glass tubing
containing an inner glass filament (outer diameter 1.5mm,
inner diameter 0.86mm; Clark Electromedical, USA) using
a Flaming-Brown P87 electrode puller (Sutter Instruments,
USA). The microelectrodes were filled with 5M potassium
acetate and had tip resistances of 30–90MO.
EJP amplitude was measured from the resting membrane
potential (RMP) to the peak amplitude following field
stimulation. The RMP was calculated by averaging the
membrane potential 100ms before stimulation. Sponta-
neous excitatory junction potentials (SEJPs) were automati-
cally detected using the ‘template’ function of Chart 5. This
function uses a correlation algorithm to compare the trace
with a selected typical SEJP in a given experiment. The
template was redefined for each cell. The algorithm applies a
rolling normalisation so that the correlation coefficient was
independent of the baseline and amplitude of any SEJP. Trace
segments with correlation coefficients of40.8 (where 1 is an
exact match) and amplitudes of 42mV were counted as
SEJPs; below an amplitude of 2mV, SEJPs were difficult to
distinguish from baseline noise.
Statistical analysis
Data were analysed using Prism 4 software (GraphPad
Software, San Diego, CA, USA). Paired or unpaired Student’s
t-tests were carried out as appropriate.
Drugs
Stock solutions of a,b-methylene ATP (a,b-MeATP) (lithium
salt), prazosin (hydrochloride), TTX (citrate), hexametho-
nium (chloride) and cyclopentolate (hydrochloride) were
dissolved in distilled water. Epibatidine (hydrochloride) was
dissolved in DMSO. The maximum final concentration
of DMSO was 0.1%. All solutions were prepared and
aliquotted before storing at "201C. All drugs passed through
a maximum of one freeze–thaw cycle. Epibatidine (di-
hydrochloride) was obtained from Tocris, UK; all other drugs
were obtained from Sigma-Aldrich (Dorset, UK). The drug
vehicle alone was without effect.
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Results
Effect of bath-applied epibatidine on EJPs and SEJPs in the mouse
vas deferens
The effect of nAChR activation on sympathetic neurotrans-
mitter release was first investigated using slow bath applica-
tion of the nAChR agonist epibatidine on the mouse vas
deferens. EJPs were evoked at a frequency of 0.33Hz and
monitored using conventional intracellular recording.
Following slow-bath application of epibatidine (100nM),
EJP amplitude was not significantly increased; 2min after
epibatidine addition, the average EJP amplitude was
10673% of the control EJP amplitude (compared with
2min before epibatidine addition; P¼0.13; nv¼14;
Figure 1a). In two experiments, a weak potentiation of EJP
amplitude occurred following the application of epibatidine.
This potentiation reached a maximum 1min after epibati-
dine addition and decreased back to control levels within
2min (Figure 1b). The frequency of SEJP occurrence was not
significantly different in the presence of epibatidine,
128726% of the control (P¼0.82, nv¼14; Figure 1a).
The effect of rapid addition of epibatidine on EJPs and SEJPs in the
mouse vas deferens
Desensitisation of nAChRs during slow application of
epibatidine may account for the lack of effect on EJPs. In
order to add epibatidine more rapidly in the electrophysio-
logical experiments, epibatidine was added directly into the
bath (producing a final bath concentration of 100nM).
When epibatidine was added, the amplitude of EJPs (during
the 120 s after addition) was 10075% of the control EJP
amplitude (during the 60 s before epibatidine addition;
P¼0.82, nv¼8, number of cells (nc)¼14; Figure 1c). In
contrast to the lack of effect on EJPs, rapid application of
epibatidine (100nM) significantly increased the frequency of
SEJP occurrence to 6297189% of the control frequency
(Po0.05, nv¼8, nc¼14; Figure 1c). In the presence of
hexamethonium, rapid application of 100nM epibatidine
had no effect on SEJP frequency: 90714% of the control
frequency (P¼0.31, nv¼8, nc¼21; Figure 1d).
Effect of bath-applied epibatidine on EJPs and SEJPs in the guinea
pig vas deferens
In the guinea pig isolated vas deferens, epibatidine (100nM)
induced a significant increase in EJP amplitude (11 of 12
tissues), reaching a maximum of 285735% of the control
amplitude 6min after addition of epibatidine. The EJP
amplitude then decreased to about 175% of the control
and remained significantly greater than the control for at
least 30min in the continued presence of epibatidine
(Po0.05; nv¼11; Figure 2a(i) and b). When the guinea pig
60 s
20 mV
EpibatidineEpibatidine
ba
20 mV
30 s
Epibatidine
HexamethoniumEpibatidine
20 mV
3 s
c d
Figure 1 The effect of slow and rapid application of epibatidine (100nM) on neurotransmitter release in the mouse vas deferens. (a) A typical
trace of the membrane potential following slow, bath application of epibatidine (100nM). EJPs were evoked at a frequency of 0.33Hz. In most
experiments, there was no clear effect of epibatidine on EJP amplitude or SEJP frequency. (b) In two experiments, a weak potentiation of EJPs
and a small increase in SEJP frequency was observed following addition of epibatidine. (c) A typical electrophysiological trace showing that the
rapid application of 100nM epibatidine had no significant effect on EJP amplitude but clearly increased SEJP frequency. Portions of the trace
before and following the addition of epibatidine are expanded to show SEJPs more clearly. The apparent depolarisation of the RMP shown in (c)
was not consistently observed. (d) A typical trace showing that following incubation with hexamethonium (100mM) for 60min, the increase in
SEJP induced by rapid application of epibatidine is abolished.
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vas deferens was pretreated with hexamethonium (100 mM)
for 1h, the effect of epibatidine was almost abolished;
EJP amplitude was 10573% of the control amplitude after
6min (Po0.05, nv¼13; Figure 2a(ii) and b). In four of 12
preparations, a transient increase in SEJP frequency occurred
reaching an average maximum of 427776% of the control
SEJP frequency between 4 and 8min (depending on the
preparation) following epibatidine addition and lasted
approximately 2min.
Effect of epibatidine on electrically evoked contraction in the
mouse vas deferens
Although the lack of an effect of epibatidine on EJP
amplitude in the mouse argues against an increase in the
evoked release of ATP, it is possible that epibatidine
selectively potentiates NA, release, which would not be
detected by intracellular recording (Burnstock and Holman,
1964). To investigate the role of noradrenaline (NA),
contraction studies were carried out. Contractions were
evoked by trains of five stimuli at a frequency of 10Hz every
30 s. The amplitude of electrically evoked contractions was
measured 2min before and 2min after epibatidine addition.
The calculated amplitude of electrically evoked contractions
did not include the amplitude of any epibatidine-induced
contraction. Following addition of epibatidine (100nM), the
amplitude of the electrically evoked contraction increased
from an average of 1.970.3mN to 2.970.3mN (Po0.05,
nv¼10; Figure 3a). A potentiation of electrically evoked
contraction was observed in all preparations tested. When
epibatidine exposure was brief (less than 120 s), this
epibatidine-induced potentiation of the electrically evoked
contraction could be consistently elicited an hour later. In
the presence of the a1-adrenoreceptor antagonist prazosin
(100nM) for 40min, the amplitude of electrically evoked
contraction was significantly reduced (Po0.05, Figure 3b).
Following addition of epibatidine, the amplitude of the
electrically evoked contraction increased from 0.370.1 to
0.670.1mN (Po0.05, nv¼10; Figure 3b).
Epibatidine-induced contraction in the mouse vas deferens
Immediately following the addition of epibatidine (100nM),
a transient contraction occurred in 5 out of 10 of the
preparations (Figure 3a). Such a contraction could be
induced in all preparations tested, by the addition of a
higher concentration of epibatidine (1 mM; Figure 4a(i) and
b). Repeated application of this higher concentration of
epibatidine, even after a 3h wash, could not reliably induce
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Figure 2 The effect of bath application of epibatidine (100nM) on
EJP amplitude in the guinea pig vas deferens. (a) Typical traces
showing membrane potential of the smooth muscle cells following
neuronal stimulation at 0.33Hz. (i) After addition of epibatidine,
there was a transient large potentiation in EJP amplitude followed by
a more sustained, smaller potentiation of EJP amplitude. (ii) In the
presence of hexamethonium (100mM) for 60min, the potentiating
effects of epibatidine were blocked. (b) Graph showing the effect
of epibatidine alone and in the presence of hexamethonium
on normalised EJP amplitude. Results shown are means7s.e.m.
from 11 (epibatidine alone) or 13 (epibatidineþhexamethonium)
experiments.
Prazosin
Epibatidine 
Epibatidine 
30 s
2 mN
a b
Stimuli
Figure 3 The effect of epibatidine (100nM) on neurogenic
contraction in the mouse vas deferens. (a) A trace showing the
effect of epibatidine (100nM) on neurogenic contraction in the
mouse vas deferens. In 50% of the preparations, a transient
contraction was observed following epibatidine addition. Neuro-
genic contractions, evoked every 30 s by a train of five stimuli at
10Hz (marked by the dots below the trace) were potentiated
following epibatidine addition. (b) Following the addition of
prazosin (100nM) for 40min, the amplitude of neurogenic contrac-
tions was still potentiated by epibatidine. On both traces, a
movement artefact is visible when epibatidine is added.
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contraction of similar amplitude. For this reason, each
experiment was conducted on a separate tissue. Following
the addition of 1mM epibatidine, the amplitude of electrically
evoked contractions was reduced (Figure 4a(i)); this reduc-
tion was not investigated further. The average amplitude
of the epibatidine-induced contraction was 9.671.1mN
(nv¼ 6; Figure 4a(i) and b). The epibatidine-induced con-
traction was significantly reduced by the voltage-gated Naþ
channel blocker TTX (300nM, a concentration that abol-
ished electrically evoked contractions) to an average of
6.370.8mN (Po0.05, nv¼6; Figure 4a(ii) and b). Following
desensitisation of P2X receptors by the addition of a,b-
MeATP (1 mM) for 1h, the average epibatidine-induced
contraction was significantly reduced from the control value
to 5.170.5mN (Po0.05, nv¼11; Figure 4a(iii) and b). It is
noteworthy that in the presence of a,b-MeATP, the epibati-
dine-induced contraction was typically prolonged (see Figure
4a(iii)), although this phenomenon was not investigated
further in the present study. In the presence of prazosin
(100nM), the average amplitude of the epibatidine-induced
contraction was 4.570.4mN (Po0.05, nv¼9; Figure 4a(iv)
and b). In the presence of both prazosin and a,b-MeATP,
a residual contraction of 1.070.3mN still remained
(Po0.05, nv¼9; Figure 4a(v) and b). No contraction was
present after pretreating with a mixture of prazosin, a,b-
MeATP and the muscarinic receptor antagonist cyclopento-
late (1 mM) for 1h (nv¼9; Figure 4a(vi) and b).
Discussion and conclusions
This investigation has shown that activation of nAChRs can
induce neurotransmitter release in both the mouse and
guinea pig vas deferens, but that the potentiation of field
stimulus-induced neurotransmitter release cannot explain
the action of epibatidine on neuronally evoked contraction
in the mouse vas deferens, as epibatidine had no significant
effect on the EJP in this species. Previous studies measuring
NA release in either rat or guinea-pig vas deferens
(Jayasundar and Vohra, 1977; Todorov et al., 1991) have
demonstrated an increase in NA release, while in the mouse,
a combination of contraction and electrophysiological
studies have suggested that ATP release is augmented by
nicotine (Brain et al., 2001). In the present work, however,
the effect of epibatidine on EJPs, and hence the release of
ATP, was weak and only detectable in some cells. This
discrepancy might be explained by the different nAChR-
subtype affinities of epibatidine and nicotine (Gerzanich
et al., 1995); for example, activation of different nAChRs
subtypes mediate different effects in other preparations such
as hippocampal slices (Alkondon et al., 1997).
It seems unlikely that a selective potentiation of NA release
over that of ATP, as previously shown in the guinea pig vas
deferens (von Ku¨gelgen and Starke, 1991a), could explain the
enhanced contraction without an effect on (purinergic) EJPs
in the mouse because a proportionally similar potentiation
of electrically evoked contractions remained when a1-
adrenoceptors were antagonised with prazosin. This observa-
tion also means that the mechanism of epibatidine-induced
potentiation of purinergic contraction does not require
postjunctional a1-adrenoceptors. Contraction studies are a
relatively indirect measurement of neurotransmitter release
and augmentation of contraction could involve a postjunc-
tional mechanism. The epibatidine-induced potentiation
of the electrically evoked contraction with no effect on EJP
amplitude could be explained by an increase in the
sensitivity of smooth muscle cells to neurotransmitter
action. An increase in sensitivity of the contraction
apparatus by a Rho kinase-dependent pathway following
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Figure 4 Epibatidine-induced contraction of mouse vas deferens.
(a) Typical traces showing a transient contraction following the
addition of epibatidine (1mM), either (i) without other drugs or (ii)
following pre-treatment with TTX 300nM for 40min, (iii) a,b-MeATP
1 mM for 1 h or (iv) prazosin 100nM for 40min. Pretreatment with (v)
both a,b-MeATP and prazosin or (vi) a,b-MeATP, prazosin and
cyclopentolate 1mM for 1 h, led to further diminution of the
epibatidine-induced contraction. (b) Bar chart showing the ampli-
tude of epibatidine-induced contractions in the presence of various
drugs. Each drug significantly reduced the amplitude of contraction
in comparison with control experiments (Po0.05). In the presence
of cyclopentolate, a,b-MeATP and prazosin, the amplitude of
contraction was below the level of detection. Results shown are
means7s.e.m. from 6 to 11 experiments in each group.
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neurotransmitter-receptor activation has been established in
many smooth muscle preparations, including the vas
deferens (Bu¨yu¨kafsar et al., 2003; Somlyo and Somlyo,
2003). However, the potential role of the Rho kinase
pathway in epibatidine-induced neurotransmitter release
(which leads to a potentiation of the electrically evoked
contraction) has yet to be investigated.
TTX reduced but did not abolish the epibatidine-induced
contraction suggesting that epibatidine-induced neurotrans-
mitter release does not solely depend on neuronal action
potential generation. It has previously been reported that
epibatidine and nicotine-induced Ca2þ transients in nerve
terminals of the mouse vas deferens, which are thought to be
responsible for the potentiation of neurotransmitter release,
are insensitive to TTX (Brain et al., 2001). Furthermore,
nicotine did not induce synchronous Ca2þ signals along the
nerve terminal; such synchronous Ca2þ transients are
characteristic of nerve action potentials, at least those
induced by field stimulation (Brain and Bennett, 1997) or
drugs such as oxaliplatin (Webster et al., 2005). In the mouse
vas deferens, the purinergic component of smooth muscle
contraction is TTX-sensitive: the smooth muscle action
potential, unusually for a smooth muscle, is generated by
voltage-gated Naþ channels (Holman et al., 1977). For this
reason, a reduction in the amplitude of the epibatidine-
induced contraction in the presence of TTX might be
entirely explained by a postjunctional effect.
A small proportion of the epibatidine-induced contraction
was sensitive to cyclopentolate, which suggests that some of
the epibatidine-induced contraction is cholinergic in origin.
There is a functional cholinergic innervation in the mouse
vas deferens (Kaschube and Zetler, 1989) and activation of
prejunctional nAChRs can potentiate electrically evoked
cholinergic neurotransmitter release in the presence of the
adrenergic nerve blocker bretylium (Cuprian et al., 2005).
The effect of nAChR activation on neurotransmitter
release was highly dependent on the rate of nAChR agonist
application. In the mouse vas deferens, epibatidine only
caused a consistent potentiation of SEJP frequency when a
rapid method of application of the drug was used. During
slow-bath application of epibatidine, the PSS perfusing the
preparation was gradually replaced with one containing
epibatidine (100nM). The nAChRs may have become
desensitised by a concentration of epibatidine insufficient
to induce neurotransmitter release. Similar desensitisation of
nAChRs by low concentrations of nAChR agonists occurs
in mouse forebrain synaptosomes (Lu et al., 1999) and rat
hippocampal slices (Dani et al., 2000). However, more rapid
activation of nAChRs initiates an increase in Ca2þ concen-
tration in presynaptic terminals that enhances the release
of many neurotransmitters (Wonnacott, 1997). Hence, it is
important to consider the rate of agonist application when
assessing the physiological relevance of any nAChR-agonist
mediated effect.
In the guinea pig vas deferens, potentiation of neuro-
transmitter release by bath-applied epibatidine appeared to
be made up of two phases: a transient large increase in
neurotransmitter release followed by a second, smaller and
more sustained potentiation. Many subtypes of nAChRs
desensitise rapidly (Quick and Lester, 2002); if such receptor
subtypes were present, continuous exposure to nAChR
agonists would cause a transient effect on neurotransmitter
release (Grady et al., 1994; Lu et al., 1999). The potentiation
of neuronally-evoked neurotransmitter release may be a
result of influx of Ca2þ through the nAChR (as most
subtypes of nAChRs are highly permeable to Ca2þ ; (Fucile,
2004). This increase in basal Ca2þ concentration produced
by nAChR activation results in a higher concentration of
nerve terminal Ca2þ being obtained during action potential
invasion; such a basal increase in Ca2þ concentration has
been observed in nerve terminals in the mouse vas deferens
in response to nicotine (Brain et al., 2001).
A sustained potentiation of electrically evoked neurotrans-
mitter release has been reported in other preparations; for
example, in mouse hippocampal slices, the potentiation
persisted following the wash out of the nAChR agonist
(Radcliffe and Dani, 1998). In the rat interpeduncular
nucleus (Covernton and Lester, 2002) and the chick lateral
spiroform nucleus (Zhu and Chiappinelli, 2002), a sustained
(415min) potentiation of neurotransmitter release in the
continual presence of nAChR agonists was reported; a
second messenger cascade was implicated in this prolonged
phase of neurotransmitter release. The mechanism of the
prolonged potentiation in the guinea pig vas deferens
remains to be determined, but a possible cause is a
population of nAChRs which are not rapidly desensitised
in the continued presence of agonists (Fenster et al., 1997).
Alternatively, influx of Ca2þ through the nAChR could lead
to changes in the intraneuronal Ca2þ concentration, which
has the potential to affect synaptic plasticity in the long term
(Berridge et al., 2000). Unfortunately, it is not possible, at
present, to monitor Ca2þ in sympathetic terminals in the
guinea-pig vas deferens (unlike the mouse; Brain and
Bennett, 1997).
In summary, these studies reveal surprising differences
in the response of the mouse and guinea pig vas deferens
to epibatidine; whereas while neurogenic contraction is
increased in both preparations, the mechanism is either
potentiation of spontaneous transmitter release (in the
mouse) to prime the muscle for contraction or an increase
in evoked release (guinea pig). Both of these mechanisms
need to be considered whenever nicotinic agonists are
shown to enhance neurogenic contractions.
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